Etrasimod compared with mesalazine for active ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial compares two oral medicines — etrasimod (a newer drug that works on the immune system) and mesalazine (a standard anti-inflammatory) — in Chinese adults with active ulcerative colitis. It aims to see which is better at controlling symptoms and is safer. If you have mild to moderate active UC, you may join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have ulcerative colitis that is currently active (mild to moderate, not severe).
- You may be new to treatment, or you may have tried standard therapies like mesalazine, steroids, or immune-suppressing drugs, but they didn't work well enough or you couldn't take them (except mesalazine — you must be able to take it).
- You must not have used advanced medications before, such as biologics (infliximab, vedolizumab) or similar small-molecule drugs (tofacitinib, ozanimod, etrasimod).
- You must not have had a recent severe flare (acute severe colitis) or have a stoma or need surgery for your UC.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the drug etrasimod in people with active ulcerative colitis (UC). It looks at how well the drug works and its safety. If you have UC that is not well controlled, this trial might help you manage your condition.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This study tests whether a new treatment made from stem cell particles (called exosomes) can help calm moderate-to-severe ulcerative colitis when standard medicines haven't worked well enough. The treatment is given directly into the vein or under the skin, and the goal is to reduce symptoms and inflammation in the colon.
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
This trial tests an oral medication called etrasimod for elderly patients with active ulcerative colitis. It aims to see if the drug is safe and effective in reducing inflammation and symptoms.
Hear when a new Etrasimod trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.